Table 3.
Fine-Gray regression for death without progression and Cox regression for overall survival.
| Variable | Univariable |
Multivariable |
||
|---|---|---|---|---|
| Death without progression | sHR (95 % CI) | P | sHR (95 % CI) | P |
| Age (y) | 1.07 (1.03–1.11) | <0.001 | ||
| Female sex | 0.97 (0.45–2.11) | 0.94 | ||
| ECOG PS (stratum) | 2.16 (1.21–3.85) | 0.009 | ||
| Cardiovascular comorbidity | 1.90 (0.85–4.25) | 0.12 | ||
| Pulmonary comorbidity | 1.93 (0.88–4.22) | 0.099 | ||
| CCI (stratum) | 2.23 (1.35–3.69) | 0.002 | 2.60 (1.50–4.49) | <0.001 |
| Adenocarcinoma (vs all else) | 1.06 (0.40–2.82) | 0.90 | ||
| N3 (vs all else) | 1.68 (0.72–3.92) | 0.23 | ||
| Left-sided primary | 1.00 (0.45–2.21) | 1 | ||
| RT dose (Gy) | 1.14 (0.97–1.33) | 0.11 | ||
| Proton therapy (vs all else) | 0.50 (0.22–1.12) | 0.092 | ||
| Proton therapy (vs IMRT) | 0.50 (0.21–1.17) | 0.11 | ||
| Internal target volume (per 100 cc) | 0.97 (0.84–1.12) | 0.67 | ||
| Mean heart dose (Gy) | 1.05 (1.01–1.08) | 0.007 | 1.06 (1.02–1.10) | 0.002 |
| Mean lung dose (Gy) | 0.97 (0.89–1.06) | 0.45 | ||
| Carbo/taxol (vs all else) | 2.03 (0.85–4.82) | 0.11 | ||
| Overall survival | HR (95 % CI) | P | HR (95 % CI) | P |
| Age (y) | 1.03 (1.02–1.05) | <0.001 | 1.04 (1.02–1.06)2 | <0.001 |
| Female sex | 0.82 (0.59–1.14) | 0.24 | ||
| ECOG PS (stratum) | 1.67 (1.25–2.30) | <0.001 | 1.59 (1.18–2.16)2 | 0.003 |
| Cardiovascular comorbidity | 1.28 (0.92–1.78) | 0.15 | ||
| Pulmonary comorbidity | 1.42 (1.02–1.98) | 0.040 | 1.48 (1.05–2.09)2 | 0.027 |
| CCI (stratum) | 1.67 (1.33–2.09) | <0.001 | ||
| Adenocarcinoma (vs all else) | 0.89 (0.60–1.33) | 0.89 | ||
| N3 (vs all else) | 1.21 (0.82–1.78) | 0.34 | ||
| Left-sided primary | 1.07 (0.77–1.50) | 0.68 | ||
| RT dose (Gy) | 0.97 (0.91–1.03) | 0.36 | ||
| Proton therapy (vs all else) | 1.09 (0.78–1.53) | 0.61 | ||
| Proton therapy (vs IMRT) | 1.12 (0.78–1.61) | 0.54 | ||
| Internal target volume (per 100 cc) | 1.08 (1.03–1.14) | 0.002 | 1.10 (1.03–1.16)2 | 0.002 |
| Mean heart dose (Gy) | 1.02 (1.01–1.04) | 0.002 | 1.03 (1.01–1.05)1 | 0.010 |
| Mean lung dose (Gy) | 1.04 (1.00–1.09) | 0.041 | 1.05 (1.01–1.10)2 | 0.027 |
| Carbo/taxol (vs all else) | 1.11 (0.80–1.55) | 0.52 | ||
sHR, subdistribution hazard ratio; y, years; PS, performance status; CCI, Charlson Comorbidity Index; RT, radiotherapy; IMRT, intensity-modulated radiotherapy; carbo/taxol, carboplatin/paclitaxel; HR, hazard ratio.
1
Model with mean heart dose, age, ECOG PS, pulmonary comorbidity, internal target volume.
2
Model with mean lung dose, age, ECOG PS, pulmonary comorbidity, internal target volume.